Advertisement

International Journal of Colorectal Disease

, Volume 25, Issue 2, pp 205–212 | Cite as

Association between adiponectin, resistin, insulin resistance, and colorectal tumors

  • Guzin GonulluEmail author
  • Hakkı Kahraman
  • Abdulkerim Bedir
  • Ahmet Bektas
  • Idris Yücel
Original Article

Abstract

Purpose

In this study, we have examined the correlation between colorectal cancer (CRC) and serum adiponectin and resistin levels, body mass index and insulin resistance.

Methods

The relation between serum adiponectin and resistin levels, obesity and insulin resistance in 36 CRC patients and 37 controls was examined.

Results

Insulin and homeostasis model assessment insulin resistance index (HOMA-IR) levels were higher, and adiponectin levels were significantly decreased in patients versus controls, whereas, resistin levels were significantly increased. A negative correlation between adiponectin, HOMA-IR, and insulin and a positive correlation between HOMA-IR, insulin, and stage were detected. There was no correlation between the stage and resistin. Adiponectin level negatively correlated with the stage. Adiponectin and resistin could play a role in colon cancer carcinogenesis, and adiponectin could be responsible for poor prognosis in colorectal cancer.

Keywords

Adiponectin Resistin Colon Tumors 

References

  1. 1.
    Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA Cancer J Clin 49:33–64CrossRefPubMedGoogle Scholar
  2. 2.
    Singh PN, Fraser GE (1998) Dietary risk factors for colon cancer in a low-risk population. Am J Epidemiol 148:761–774PubMedGoogle Scholar
  3. 3.
    Slattery ML, Potter J, Caan B, Edwards S, Coates A, Ma KN, Berry TD (1997) Energy balance and colon cancer—beyond physical activity. Cancer Res 57:75–80PubMedGoogle Scholar
  4. 4.
    Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, Gershenson DM, Lu KH (2006) Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 106:2376–2381CrossRefPubMedGoogle Scholar
  5. 5.
    Chasan-Taber S, Rimm EB, Stampfer MJ, Spiegelman D, Colditz GA, Giovannucci E, Ascherio A, Willett WC (1996) Reproducibility and validity of a self-administered physical activity questionnaire for male health profesionals. Epidemiology 7:81–86CrossRefPubMedGoogle Scholar
  6. 6.
    Lee IM, Sesso HD, Paffenbarger RS Jr (1999) Physical activity and risk of lung cancer. Int J Epidemiol 28:620–625CrossRefPubMedGoogle Scholar
  7. 7.
    Kershaw EE, Flier JSJ (2004) Adipose tissue as an endocrine organ. Clin Endocrinol Metab 6:2548–2556Google Scholar
  8. 8.
    Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Lannom L, Hoover RN (1992) Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 167:1317–1325PubMedGoogle Scholar
  9. 9.
    Siiteri PK (1987) Adipose tissue as a source of hormones. Am J Clin Nutr 1:277–282Google Scholar
  10. 10.
    Fantuzzi G (2005) Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 115:911–919CrossRefPubMedGoogle Scholar
  11. 11.
    Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T (2003) Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762–769CrossRefPubMedGoogle Scholar
  12. 12.
    Okamoto Y, Kihara S, Ouchi N, Nishida M, Arita Y, Kumada M, Ohashi K, Sakai N, Shimomura I, Kobayashi H, Terasaka N, Inaba T, Funahashi T, Matsuzawa Y (2002) Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106:2767–2770CrossRefPubMedGoogle Scholar
  13. 13.
    Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, Noguchi S (2003) Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res 9:5699–5704PubMedGoogle Scholar
  14. 14.
    Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS (2005) Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 97:1688–1694PubMedCrossRefGoogle Scholar
  15. 15.
    Lukanova A, Söderberg S, Kaaks R, Jellum E, Stattin P (2006) Serum adiponectin is not associated with risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 15:401–402CrossRefPubMedGoogle Scholar
  16. 16.
    Diez JJ, Iglesias P (2003) The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol 148:293–300CrossRefPubMedGoogle Scholar
  17. 17.
    Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83CrossRefPubMedGoogle Scholar
  18. 18.
    Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595–1599PubMedGoogle Scholar
  19. 19.
    Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM (2002) Plasma adiponectin levels in overweight and obese Asians. Obes Res 10:1104–1110CrossRefPubMedGoogle Scholar
  20. 20.
    Karapanagiotou EM, Tsochatzis EA, Dilana KD (2008) The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer. Lung Cancer 61:391–397CrossRefPubMedGoogle Scholar
  21. 21.
    Kang JH, Yu BY, Youn DS (2007) Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 22:117–121CrossRefPubMedGoogle Scholar
  22. 22.
    Kumor A, Daniel P, Pietruczuk M, Małecka-Panas E (2009) Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis 24:275–278CrossRefPubMedGoogle Scholar
  23. 23.
    Eraslan E, Turkay C, Koktener A, Koca C, Uz B, Bavbek N (2009) Association of visceral fat accumulation and adiponectin levels with colorectal neoplasia. Dig Dis Sci 54:862–868CrossRefGoogle Scholar
  24. 24.
    Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA (2004) An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1:45CrossRefGoogle Scholar
  25. 25.
    Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935CrossRefPubMedGoogle Scholar
  26. 26.
    Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA (2001) The hormone resistin links obesity to diabetes. Nature 409:307–312CrossRefPubMedGoogle Scholar
  27. 27.
    Nagaev I, Smith U (2001) Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 285:561–564CrossRefPubMedGoogle Scholar
  28. 28.
    TNM classification of malignant tumours. Sobin L.H, Wittekind Ch. Sixth Edition, 2002Google Scholar
  29. 29.
    Gordon ME, McKeever KH (2005) Diurnal variation of ghrelin, leptin, and adiponectin in standardbred mares. J Anim Sci 10:2365–2371Google Scholar
  30. 30.
    Yildiz BO, Suchard MA, Wong ML, McCann SM, Licinio J (2004) Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. PNAS 101:10434–10439CrossRefPubMedGoogle Scholar
  31. 31.
    Gavrila A, Peng CK, Chan JL, Mietus JE, Goldberger AL, Mantzoros CS (2003) Diurnal and ultradian dynamics of serum adiponectin in healthy men: comparison with leptin, circulating soluble leptin receptor, and cortisol patterns. J Clin Endocrinol Metab 6:2838–2843CrossRefGoogle Scholar
  32. 32.
    Oliver P, Ribot J, Rodríguez AM, Sánchez J, Picó C, Palou A (2006) Resistin as a putative modulator of insulin action in the daily feeding/fasting rhythm. Pflugers Arch 3:260–267CrossRefGoogle Scholar
  33. 33.
    McTernan PG, McTernan CL, Chetty R, Jenner K, Fisher FM, Lauer MN, Crocker J, Barnett AH, Kumar S (2002) Increased resistin gene and protein expression in human abdominal adipose tissue. J Clin Endocrinol Metab 87:2407CrossRefPubMedGoogle Scholar
  34. 34.
    Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F (2001) Risk factors and life expectancy research group. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 10:937–941PubMedGoogle Scholar
  35. 35.
    Kelesidis I, Kelesidis T, Mantzoros CS (2006) Adiponectin and cancer: a systematic review. Br J Cancer 94:1221–1225CrossRefPubMedGoogle Scholar
  36. 36.
    Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, Funahashi T, Cao Y (2004) Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A 101:2476–2481CrossRefPubMedGoogle Scholar
  37. 37.
    Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y (2000) Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723–1732PubMedGoogle Scholar
  38. 38.
    Fujisawa T, Endo H, Tomimoto A, Sugiyama M, Takahashi H, Saito S, Inamori M, Nakajima N, Watanabe M, Kubota N, Yamauchi T, Kadowaki T, Wada K, Nakagama H, Nakajima A (2008) Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut 57:1531–1538CrossRefPubMedGoogle Scholar
  39. 39.
    Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H (2005) Plasma adiponectin and gastric cancer. Clin Cancer Res 11:466–472CrossRefPubMedGoogle Scholar
  40. 40.
    Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S (2005) Prostate cancer and adiponectin. Urology 65:1168–1172CrossRefPubMedGoogle Scholar
  41. 41.
    Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, Trichopoulos D (2004) Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102–1107CrossRefPubMedGoogle Scholar
  42. 42.
    Ferroni P, Palmirotta R, Spila A, Martini F, Formica V, Portarena I, Del Monte G, Buonomo O, Roselli M, Guadagni F (2007) Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res 27:483–489PubMedGoogle Scholar
  43. 43.
    Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y (2001) PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 9:2094–2099CrossRefGoogle Scholar
  44. 44.
    Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111:932–939CrossRefPubMedGoogle Scholar
  45. 45.
    Kawanami D, Maemura K, Takeda N, Harada T, Nojiri T, Imai Y, Manabe I, Utsunomiya K, Nagai R (2004) Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun 314:415–419CrossRefPubMedGoogle Scholar
  46. 46.
    Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548–2556CrossRefPubMedGoogle Scholar
  47. 47.
    Utzschneider KM, Carr DB, Tong J, Wallace TM, Hull RL, Zraika S, Xiao Q, Mistry JS, Retzlaff BM, Knopp RH, Kahn SE (2005) Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 48:2330–2333CrossRefPubMedGoogle Scholar
  48. 48.
    Monzillo LU, Hamdy O, Horton ES, Ledbury S, Mullooly C, Jarema C, Porter S, Ovalle K, Moussa A, Mantzoros CS (2003) Effect of lifestyle modification on adipokine levels in obese subjects with insulin resistance. Obes Res 11:1048–1054CrossRefPubMedGoogle Scholar
  49. 49.
    Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY, Cho YM, Park YJ, Kim SY, Lee HK, Park KS (2004) Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 89:150–156CrossRefPubMedGoogle Scholar
  50. 50.
    Shacter E, Weitzman SA (2002) Chronic inflammation and cancer. Oncology 16:217–226PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Guzin Gonullu
    • 1
    Email author
  • Hakkı Kahraman
    • 2
  • Abdulkerim Bedir
    • 3
  • Ahmet Bektas
    • 4
  • Idris Yücel
    • 1
  1. 1.Department of Medical OncologyOndokuz Mayıs University Medical SchoolSamsunTurkey
  2. 2.Department of EndocrinologyOndokuz Mayıs University Medical SchoolSamsunTurkey
  3. 3.Department of BiochemistryOndokuz Mayıs University Medical SchoolSamsunTurkey
  4. 4.Department of GastroenterologyOndokuz Mayıs University Medical SchoolSamsunTurkey

Personalised recommendations